Schrödinger, Inc. (SDGR)
- Simply Wall St.
We're Not Very Worried About Schrödinger's (NASDAQ:SDGR) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
- Insider Monkey
Is Schrodinger (SDGR) a Smart Long-term Buy?
Baron Health Care Fund recently published its third-quarter commentary – a copy of which can be downloaded here. During the third quarter of 2020, the Baron Health Care Fund returned 11.64% (institutional shares). In comparison, the benchmark S&P 500 Index was up 8.93%, while the Russell 3000 Health Care Index was up 6.48%. You should […]
- Business Wire
Schrödinger Presents Data from Its MALT1 Inhibitor Program at the American Society of Hematology (ASH) 2020 Annual Meeting
Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, presented preclinical data from its wholly-owned MALT1 inhibitor program in B-cell lymphomas at the virtual 62nd American Society of Hematology (ASH) Annual Meeting. MALT1, mucosa-associated lymphoid tissue lymphoma translocation protein 1, is considered a potential therapeutic target for several non-Hodgkin’s B-cell lymphomas as well as chronic lymphocytic leukemia (CLL). Schrödinger scientists have identified novel MALT1 inhibitors that have shown strong anti-tumor activity in preclinical models alone and in combination with ibrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, and venetoclax, a B-cell lymphoma 2 (BCL-2) inhibitor, two anti-cancer therapies used to treat certain B-cell lymphomas and CLL.
